Article

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

2023-09-05

Abstract excerpt

BRAF is one of the most frequently mutated oncogenes, with an overall frequency of about 50%. Targeting BRAF and its effector mitogen-activated protein kinase kinase 1/2 (MEK1/2) is now a key therapeutic strategy for BRAF-mutant tumors, and therapies based on dual BRAF/MEK inhibition showed significant efficacy in a broad spectrum of BRAF tumors. Nonetheless, BRAF/MEK inhibition therapy is not always effective for...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 76f35010-7f7c-5141-a60c-4c0bd508853b
DOI: 10.20944/preprints202309.0185.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2DOI 10.20944/preprints202309.0185.v1Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated TumoursSemantic proximity Read

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.Semantic proximity Read

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read